本研究（FAST）是对老年高胆固醇血症患者施行降脂治疗的有效性与安全性进行详细评价。FAST研究包括246名高胆固醇血症患者，其中76名患者为治疗组（75岁，患者随机被分为普罗布考治疗组(500 mg/day)和普法他汀治疗组(10 mg/day)），其余为对照组，随访两年。在年龄75岁以上（包括75岁）的患者中，普罗布考和普法他汀均能显著降低其颈动脉内膜中层厚度（IMT）；在年龄75岁以下的患者中，降脂治疗同样显著降低其IMT。在年龄75岁以上（包括75岁）的接受普罗布考治疗的患者中，发生全因死亡和主要冠脉事件的相对概率分别为0.15和0.12。总之，普罗布考除治疗高胆固醇青年患者外，同样能降低老年患者的心血管疾病发病率。
The present study involved a detailed post hoc comparison of the efficacy and safety of lipid-lowering therapy in elderly hypercholesterolemic patients from the Fukuoka Atherosclerosis Trial (FAST). The FAST cohort of 246 hypercholesterolemic patients included 76 patients who were (75 years old. Patients were randomized to receive probucol (500 mg/day) or pravastatin (10 mg/day) therapy, or to a control group (diet alone), and then were followed for 2 years. In patients > or = 75 years old, either probucol or pravastatin achieved a significant reduction of carotid intima-media thickness (IMT).In patients <75 years old,lipid-lowering therapy also achieved a significant reduction of IMT.In patients > or = 75 years old receiving probucol, the relative risk (95% confidence interval) of all-cause mortality was 0.15 (0.02 to 1.28) and that for major coronary events was 0.12 (0.02 to 1.04). In conclusion, probucol reduced the incidence of cardiovascular disease in elderly hypercholesterolemic patients as well as younger patients.
|
|
